Key Publication Snapshot 5: TRK xDFG mutations trigger a sensitivity switch from type I to II kinase inhibitors
Key Publication Snapshot 5: TRK xDFG mutations trigger a sensitivity switch from type I to II kinase inhibitors
Dr Luca Toschi
Dr Luca Toschi (NTRK CONNECT) has developed this resource with COR2ED.
Dr Luca Toschi
Medical Oncologist
Humanitas Cancer Center
Italy
Dr Luca Toschi has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
AstraZeneca, BMS, Boehringer, Ingelheim, Lilly, MSD, Pfizer and Roche.
|
5 min
|
Dec 2020
This programme was made for you: your opinion matters
Share your feedback in just 4 clicks and help us to continue to create the content you need.
I agree that this educational programme:
Was valuable to me:
1/4
Has improved my knowledge of this topic:
2/4
Is likely to change my clinical practice:
3/4
Was balanced and unbiased:
4/4
download resources
This programme was made for you: your opinion matters
Share your feedback in just 4 clicks and help us to continue to create the content you need.
I agree that this educational programme:
Was valuable to me:
1/4
Has improved my knowledge of this topic:
2/4
Is likely to change my clinical practice:
3/4
Was balanced and unbiased:
4/4
PRECISION ONCOLOGY CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from AstraZeneca and Bayer.